Business
-
Insys Therapeutics has filed for Chapter 11 bankruptcy and plans to sell “substantially all of the company’s assets,” the company said. Insys’s pipeline includes inhaled dronabinol, intranasal epinephrine, and intranasal naloxone. NDA submissions for the… Read more . . .
-
Medical Developments International (MVP) announced that Mundipharma has acquired exclusive Australian distribution rights for the Penthrox methoxyflurane inhaler. Mundipharma already has the rights to market Penthrox in most of Europe. Mundipharma Australia and New Zealand… Read more . . .
-
Nasal drug delivery specialist Kurve Technology announced that the US Department of Defense (DoD) has awarded the company a contract for testing a formulation for the treatment of traumatic brain injury (TBI). The Kurve ViaNase… Read more . . .
-
DPI developer TFF Pharmaceuticals said that is has raised $8.17 million through a Series A preferred stock offering and that it will use the funds for R&D. In April 2018, the company announced that it… Read more . . .
-
Acerus Pharmaceuticals said that it has acquired exclusive worldwide rights to technology related to intranasal delivery of testosterone from the University of Texas at Austin. The company said that the agreement covers the use of… Read more . . .
-
According to BlueWillow Biologics, the University of Michigan has been issued US patent No. 10,138,279 which covers an intranasal anthrax vaccine formulated with BlueWillow’s NanoVax adjuvant. BlueWillow (formerly NanoBio) is a spin out from the University… Read more . . .
-
Insmed Incorporated said that a just-closed public stock offering generated net proceeds of about $235.5 million that will be used for continuing commercialization of Arikayce amikacin liposome inhalation suspension (ALIS). The offering of 9,615,385 shares of… Read more . . .
-
Vectura Group and Sosei Group each said that they are owed $2.5 million milestone payments from Novartis after the EU accepted Novartis’s MAA for its QVM149 indacaterol/glycopyrronium/mometasone furoate DPI for the treatment of asthma that… Read more . . .
-
MannKind Corporation has announced that signed a marketing and distribution agreement with Australasian Medical & Scientific Ltd division AMSL Diabetes for commercialization of Afrezza inhaled insulin in Australia. AMSL Diabetes will take responsibility for getting… Read more . . .
-
Pneuma Respiratory has announced a licensing agreement with Nanjing Leads Biolabs subsidiary Leads Biolabs, Inc. for rights to develop Leads monoclonal antibodies and fusion protein molecules for delivery using Pneuma’s digital soft mist inhaler. Pneuma… Read more . . .

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
May 30-June 2: ISAM Congress 2027, Dublin, Ireland
June 23: SMI London, London, UK

